2 | 1.是否建立了防止控股股东、实际控制人及其关 | | | --- | --- | | 联人直接或者间接占用上市公司资金或者其他资 | √ | | 源的制度 | | | 2.控股股东、实际控制人及其关联人是否不存在 | | | 直接或者间接占用上市公司资金或者其他资源的 | √ | | 情形 | | | 3.关联交易的审议程序是否合规且履行了相应的 | √ | | 信息披露义务 | | | 4.关联交易价格是否公允 | √ | | 5.是否不存在关联交易非关联化的情形 | √ | | 6.对外担保审议程序是否合规且履行了相应的信 | √ | | 息披露义务 | | | 7.被担保方是否不存在财务状况恶化、到期不清 | √ | | 偿被担保债务等情形 | | | 8.被担保债务到期后如继续提供担保，是否重新 | √ | | 履行了相应的审批程序和披露义务 | | | （五）募集资金使用 | | | 现场检查手段（包括但不限于本指引第33条所列） | | | 1.是否在募集资金到位后一个月内签订三方监管 | √ | | 协议 | | | 2.募集资金三方监管协议是否有效执行 | √ | | 3.募集资金是否 ...

一、保荐工作概述 | 项目 | | | | | | 工作内容 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1.公司信息披露审阅情况 | | | | | | | | | | | | | | | （1）是否及时审阅公司信息披露文件 | | | | | | 是 | | | | | | | | | （2）未及时审阅公司信息披露文件的次数 | | | | | | 无 | | | | | | | | | 2.督导公司建立健全并有效执行规章制度 | | | | | | | | | | | | | | | 的情况 | | | | | | | | | | | | | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | | | | | | | | | | 是 | | | | | 度、募集资金管理制度、内控制度、内部 | | | | | | | | | | | | | | | 审计制度、关联交易制度） | | | | | | | | ...

Core Viewpoint - The company reported a significant decline in revenue and profit for the year 2024, primarily due to reduced sales of high-margin monitoring equipment and the impact of centralized procurement policies [1][4]. Revenue Performance - The total revenue for 2024 was 1.06 billion yuan, a year-on-year decrease of 11.18% [1]. - Sales revenue from monitoring equipment dropped by 1.17 billion yuan, a staggering decline of 69.77%, directly affecting overall profit performance [4]. - The renal medical segment showed relative stability with sales revenue of 804 million yuan, a slight increase of 0.91% [4]. Product Development and Innovation - The company continued to invest in R&D, launching several innovative products, including the Biofluid fluid balance management system and the BioView anesthesia video laryngoscope [5]. - New blood dialysis devices were introduced, which received regulatory approval, enhancing the product line and improving patient experience [6]. Market Strategy and Challenges - Centralized procurement policies significantly impacted the company's performance, leading to price pressures on blood dialysis consumables [7]. - The company successfully won bids in a procurement alliance across 22 provinces but faced limitations on revenue growth due to pricing pressures [7]. - To counter these challenges, the company is actively expanding into overseas markets and optimizing internal management to enhance operational efficiency [7].

证券代码：300246 证券简称：宝莱特 公告编号：2025-026 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于公司董事、副总裁兼核心技术人员退休离职的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）董事会于2025年4月 28日收到公司董事、副总裁兼核心技术人员梁瑾女士的书面辞呈。梁瑾女士因退 休申请辞去公司董事、副总裁兼核心技术人员等职务，上述职务原定任期至公司 第八届董事会届满（即2022年12月26日至2025年12月25日）。梁瑾女士辞去上述 职务后，不再担任公司及子公司任何职务，将不再被认定为公司核心技术人员。 根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》《公司章程》等相关规 定，梁瑾女士的辞职申请自书面辞呈送达公司董事会之日起生效。梁瑾女士的离 职不会导致公司董事会成员低于法定最低人数，其离职不会影响公司及董事会的 正常运作，公司将按照相关规定尽快完成董事补选的工作。 梁瑾女士在公 ...

财通证券股份有限公司 （二）核心技术人员参与的项目及专利情况 梁瑾女士在公司任职期间参与的研发项目工作，目前已经完成工作交接，其 辞任上述职务不会对项目的研发进程产生重大不利影响。梁瑾女士在任职期间参 与研发的知识产权均归公司所有，不存在涉及职务成果、知识产权的纠纷或潜在 纠纷，梁瑾女士辞任上述职务不影响公司知识产权的完整性。 （三）履行保密义务情况 关于广东宝莱特医用科技股份有限公司 核心技术人员离职的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为广东 宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）的持续督导保 荐机构，根据有关法律法规和规范性文件的要求，对宝莱特核心技术人员离职的 事项进行了审慎核查，核查情况如下： 一、技术人员离职的具体情况 （一）核心技术人员的具体情况 梁瑾，女，1974 年生，中国国籍，无境外永久居留权，本科学历。1996 年 加盟宝莱特电子，历任硬件工程师、项目经理、系统工程师、研发中心总监。现 任公司董事、副总裁、总工程师，全资子公司辽宁恒信生物科技有限公司董事、 孙公司南昌宝莱特医疗器械有限责任公司董事。 截至本核查意见出具日，梁瑾女士直接 ...

Financial Performance - In Q1 2025, the company's operating revenue was 247,732,813.14 CNY, a decrease of 7.17% compared to the same period last year [5] - The net profit attributable to shareholders was 14,448,489.46 CNY, showing a significant increase of 298.35% year-on-year [5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 338,833.92 CNY, up 105.49% from the previous year [5] - Basic earnings per share reached 0.0546 CNY, reflecting a year-on-year growth of 298.54% [5] Market and Policy Impact - The implementation of new policies, such as the "Action Plan for Promoting Large-Scale Equipment Updates and Consumer Goods Replacement," is expected to positively impact the company's monitoring and dialysis product lines [2] - Increased demand for monitoring equipment is anticipated due to the policy-driven replacement of outdated devices in public hospitals and grassroots medical institutions [2] - The company aims to leverage these policies to enhance market share through product upgrades and expanded marketing efforts [2] Industry Trends - The blood dialysis market is projected to experience increased competition over the next 3-5 years, with market concentration expected to rise as leading companies consolidate their positions [3] - Technological advancements, such as home dialysis and smart monitoring, are anticipated to become new growth points, favoring early adopters [4] - The emergence of new markets, particularly in China and India, is expected to challenge international giants as local companies offer competitive pricing [4] Product Development and Innovation - The company plans to focus on developing intelligent medical devices that address clinical needs, with an emphasis on innovative solutions in the renal care sector [5] - New products, including a polypropylene blood dialysis device and specialized dialysis solutions, are set to be launched in 2024 [4] - The company is also working on a new CRRT machine that will integrate with its overall life support solutions [5] Revenue Breakdown - In 2024, the life information and support segment generated sales revenue of 243,502,800 CNY, accounting for approximately 23% of total revenue [6] - The renal medical segment achieved sales revenue of 804,300,500 CNY, representing about 76% of total revenue [6] Strategic Focus for 2025 - The company will concentrate on its two main business areas, aiming to capitalize on opportunities from medical infrastructure expansion and domestic product substitution [8] - Plans include enhancing the penetration of high-margin products in critical care and surgical anesthesia [8] - The company will also strengthen its supply chain and production efficiency to align with procurement policies and improve overall operational effectiveness [8]

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 纳入评价范围的主要业务和事项包括：治理架构、内部审计、人力资源、授 权审批控制、预算控制、绩效考评、运营分析、子公司管控、对外投资与提供财 务资助、供应链管控、财务管控、募集资金管理、信息披露管理、信息与沟通、 内部监督等。 2024 年度内部控制自我评价报告的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为广东 宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）的持续督导保 荐机构，根据有关法律法规和规范性文件的要求，对宝莱特《2024年度内部控制 自我评价报告》进行了审慎核查，具体情况如下： 一、财通证券对公司内部控制的核查工作 保荐代表人通过审阅公司内控相关制度、查阅股东大会、董事会、监事会会 议记录，与企业相关人员进行交流等措施，从公司内部控制的环境、业务控制、 信息系统控制、会计管理控制和内部控制的监督等多方面对其内部控制的完整性、 合理性和有效性进行了核查。 二、内部控制评价工作情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 纳入评价范围的主要单位包 ...

广东宝莱特医用科技股份有限公司 二〇二四年度 内部控制审计报告 广东宝莱特医用科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了广东宝莱特医用科技股份有限公司（以下简称宝莱特公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是宝莱特公司董事会的责任。 致同会计师事务所（特殊普通合伙） 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制审计报告 致同审字（2025）第 442A016609 号 我们认为，宝莱特公司于 2024 年 12 月 31 日按照《企业内部控制基本规 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 致同会计师事务所 （特殊普通合伙） 中国注册会计师 王莹 中国 ...

关于广东宝莱特医用科技股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同会计师事务所（特殊普通合伙） 目 录 关于广东宝莱特医用科技股份有限公司 2024 年度募集资金 存放与实际使用情况鉴证报告 广东宝莱特医用科技股份有限公司 2024 年度募集资金 存放与实际使用情况的专项报告 关于广东宝莱特医用科技股份有限公司 2024 年度募集资金存放与实际使用情况鉴证报告 致同专字（2025）第 442A009956 号 广东宝莱特医用科技股份有限公司全体股东： 1-6 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 我们接受委托，对后附的广东宝莱特医用科技股份有限公司（以下简称 宝莱特公司）《2024 年度募集资金存放与实际使用情况的专项报告》（以下 简称 "专项报告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求（2022 年修订）》和《深圳证券交易所 ...